TAK 117

Drug Profile

TAK 117

Alternative Names: INK-1117; MLN-1117; TAK-117

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator Intellikine
  • Developer European Network for Translational Research in Ovarian Cancer (EUTROC); Takeda; Takeda Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; 1-phosphatidylinositol 4-kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Endometrial cancer; Renal cell carcinoma
  • Phase I/II Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 29 Nov 2016 Adverse event and efficacy results from a phase Ib trial in Solid tumour presented at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 01 Jun 2016 Millennium Pharmaceuticals completes a pharmacokinetic phase I trial in Healthy volunteers in USA (NCT02625259)
  • 01 Jun 2016 Phase-II clinical trials in Endometrial cancer (Combination therapy, Late-stage disease, Metastatic disease) in United Kingdom, Germany, Canada, Belgium, Australia, USA (PO) (EudraCT2014-005394-37; NCT02725268) after June 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top